|
1. Biologie
|
|
|
|
4.11 Dép., diag. & prono. - Ovaire
|
|
|
The Yet Unrealized Promise of Ovarian Cancer Screening [JAMA Oncology]
|
|
|
|
|
|
Ovarian
cancer mortality has remained largely unchanged over the last 5
decades. Early detection may yet prove to be effective, but the
mortality reduction is likely to be modest. For now, the USPSTF has
provided sound clinical and public health recommendations against
screening for average-risk, asymptomatic women.
|
|
|
|
|
|
|
4.12 Biopsies liquides
|
|
|
Liquid Biopsies: Past, Present, and Future [ACS]
|
|
|
|
|
|
But
it’s one thing, Lichtenfeld says, to use a liquid biopsy to test a
patient who you know already has cancer, as they did for their study.
“It’s completely different to translate that into a situation when
you’re screening millions of people who have no evidence of cancer,” he
says.
|
|
|
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5. Traitements
|
|
|
Precision Medicine: Hope or Hype? [The ASCO Post]
|
|
|
|
|
|
“At
the end of the day, biology is still messy and science is still hard,”
Dr. Sledge continued. “Precision medicine is not a panacea; it’s a tool.
And like all tools, it needs to be used appropriately. If not, it will
not work.”
|
|
|
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
New Cancer Treatment Approach Targets Circadian Clock [NCI]
|
|
|
|
|
|
Two
compounds that target components of the circadian clock killed several
types of cancer cells in the lab and slowed the growth of brain tumors
in mice without harming healthy cells, the study investigators reported.
The NCI-funded study was published January 18 in Nature.
|
|
|
|
|
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12 Immunothérapies
|
|
|
Researchers develop novel immunotherapy to target colorectal cancer [Yale News]
|
|
|
|
|
|
“We
found that this Wnt inhibitor, DKK2, which was thought to inhibit tumor
formation, promoted tumors through suppression of tumor immunity,” Wu
said. Additionally, they learned “if you inactivate, or neutralize, or
blockade this inhibitor, it causes reduction of tumor formation through
activation of the host’s immune system.”
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
5.5.3 ASCO (prostate)
|
|
|
Richard Lehman’s journal reviews—12 February 2018 - Et tu, apalutamide [BMJ]
|
|
|
|
|
|
Apalutamide
is a me-too drug and as such needs to prove its superiority over others
in the class: but in this manufacturer funded study, it was compared
with placebo rather than bicalutamide. I searched for a justification in
the accompanying review article on the management of prostate cancer
but I couldn’t find any. But ethics approval was obtained in 26
countries, so I must be missing something.
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
Precision Medicine for Everyone [NEJM Catalyst]
|
|
|
|
|
|
Fully
realizing the promises of precision medicine for everyone will require
cultural humility, a process of self-reflection and honesty to build
trustworthy relationships, and precision engagement.
|
|
|
|
|
|
|
6.1 Observation
|
|
|
Obesity Tied to Survival in Men With Melanoma [NY Times]
|
|
|
|
|
|
“The
magnitude of the effect and the dose-response relationship point to
there being a biological underpinning to this,” she said. “But we need
to emphasize that obesity is still a risk factor for many diseases,
including 13 different types of cancer. The most important thing is
still preventing obesity.”
|
|
|
|
|
|
|
6.11 Patients
|
|
|
'My sister died of lung cancer but never smoked' [BBC News]
|
|
|
|
|
|
Paula
Chadwick, chief executive of the Roy Castle Lung Cancer Foundation,
paints a stark picture of why research and treatment is so poorly
funded. She argues that it is almost a "Cinderella" disease, because of
the stigma that comes with the idea that it might be self-inflicted.
|
|
|
|
|
|
|
6.4 Médico-éco
|
|
|
|
|
6.6 Publications
|
|
|